Efficacy and safety of first-line (1L) nivolumab plus relatlimab (NIVO + RELA) versus NIVO plus ipilimumab (NIVO + IPI) in advanced melanoma: An indirect treatment comparison (ITC) using patient-level data (PLD).

MLA

Schadendorf, Dirk, et al. “Efficacy and Safety of First-Line (1L) Nivolumab plus Relatlimab (NIVO + RELA) versus NIVO plus Ipilimumab (NIVO + IPI) in Advanced Melanoma: An Indirect Treatment Comparison (ITC) Using Patient-Level Data (PLD).” Journal of Clinical Oncology, vol. 41, June 2023, p. 9552. EBSCOhost, https://doi.org/10.1200/JCO.2023.41.16_suppl.9552.

APA

Schadendorf, D., Tawbi, H. A., Lipson, E. J., Hodi, F. S., Ascierto, P. A., Larkin, J., Lao, C. D., Grob, J.-J., Ejzykowicz, F., Moshyk, A., Horton, V. G., Zhou, J., Xin, Y., Palaia, J., McDonald, L., Keidel, S., Salvatore, A., Sakkal, L. A., & Long, G. V. (2023). Efficacy and safety of first-line (1L) nivolumab plus relatlimab (NIVO + RELA) versus NIVO plus ipilimumab (NIVO + IPI) in advanced melanoma: An indirect treatment comparison (ITC) using patient-level data (PLD). Journal of Clinical Oncology, 41, 9552. https://doi.org/10.1200/JCO.2023.41.16_suppl.9552

Chicago

Schadendorf, Dirk, Hussein A. Tawbi, Evan J. Lipson, F. Stephen Hodi, Paolo Antonio Ascierto, James Larkin, Christopher D. Lao, et al. 2023. “Efficacy and Safety of First-Line (1L) Nivolumab plus Relatlimab (NIVO + RELA) versus NIVO plus Ipilimumab (NIVO + IPI) in Advanced Melanoma: An Indirect Treatment Comparison (ITC) Using Patient-Level Data (PLD).” Journal of Clinical Oncology 41 (June): 9552. doi:10.1200/JCO.2023.41.16_suppl.9552.